Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.3599
-0.0231 (-6.03%)
At close: Mar 4, 2026, 4:00 PM EST
0.3402
-0.0197 (-5.47%)
After-hours: Mar 4, 2026, 4:15 PM EST
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $72.10K. In the year 2024, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
70.75
Revenue / Employee
$24,034
Employees
3
Market Cap
4.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72.10K | - | - |
| Dec 31, 2023 | 72.10K | - | - |
| Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
| Dec 31, 2021 | 71.26K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 2.86M |
| Cyclerion Therapeutics | 2.86M |
| BioRestorative Therapies | 383.40K |
| VivoSim Labs | 142.00K |
| Bio Green Med Solution | 81.00K |
SILO News
- 9 days ago - Silo Pharma Announces Share Buyback Program - GlobeNewsWire
- 14 days ago - Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio - GlobeNewsWire
- 2 months ago - Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 - GlobeNewsWire
- 3 months ago - Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD - GlobeNewsWire
- 4 months ago - Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain - GlobeNewsWire
- 4 months ago - Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program - GlobeNewsWire
- 5 months ago - Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth - GlobeNewsWire
- 5 months ago - Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) - GlobeNewsWire